What's new? Log in Free sign up

Filing search / Innovation Pharmaceuticals Inc. / "Incentive"

Search information

Innovation Pharmaceuticals Inc.

Companies

"Incentive"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

100 results

Newest first Best match first

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

$260,000 and $229,000, respectively. 13. Equity Incentive Plans and Stock-Based Compensation 2016 Equity Incentive Plan (the “2016 Plan”) On June 30 … The following table summarizes all stock option activity under the Company’s equity incentive plans: Number of Stock Options Weighted Average Exercise

20 Nov 23

4:05pm

IPIX Innovation Pharmaceuticals Inc.

compensation expense incurred by the Company for employees, non-employees and directors in connection with its equity incentive plan is based on ASC 718 … into the Company’s Class A common stock at $0.50 per share. On December 29, 2010, the Company issued 18,000,000 Equity Incentive Options to purchase Class B

28 Sep 23

9:00am

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

incentive plan is based on ASC 718, and the fair market value of the equity awards is measured at the grant date. Awards with service-based vesting … share. On December 29, 2010, the Company issued 18,000,000 Equity Incentive Options to purchase Class B common stock to Mr. Ehrlich, which

15 May 23

8:01am

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

The stock-based compensation expense incurred by the Company for employees, non-employees and directors in connection with its equity incentive plan … share. On December 29, 2010, the Company issued 18,000,000 Equity Incentive Options to purchase Class B common stock to Mr. Ehrlich, which

10 Nov 22

4:06pm

IPIX Innovation Pharmaceuticals Inc.

in October, 2021 (see note 14. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding of the Notes to Consolidated … Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding of the Notes to Consolidated Financial Statements included

28 Sep 22

4:00pm

Entry into a Material Definitive Agreement

Quarterly report

13 May 22

4:07pm

zvsaqid fpi5emar1e

Quarterly report

14 Feb 22

4:00pm

Quarterly report

9 Nov 21

1:44pm

Departure of Directors or Certain Officers

Departure of Directors or Certain Officers

27 Sep 21

4:16pm

Quarterly report

13 May 21

8:00am

Quarterly report

22 Feb 21

11:19am

deub2nm2q6hvcmfz

Prospectus supplement for primary offering

Entry into a Material Definitive Agreement

Quarterly report

16 Nov 20

9:00am

14 Sep 20

4:50pm

Prospectus supplement for primary offering

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

Prev
1
2
3
4
5
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.